TITLE

Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically Relevant Bolus Treatment with Bortezomib

AUTHOR(S)
Shabaneh, Tamer B.; Downey, Sondra L.; Goddard, Ayrton L.; Screen, Michael; Lucas, Marcella M.; Eastman, Alan; Kisselev, Alexei F.
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little attention has been paid as to whether in vitro studies are representative of this level of inhibition. Patients receive bortezomib as an intravenous or subcutaneous bolus injection, resulting in maximum proteasome inhibition within one hour followed by a gradual recovery of activity. In contrast, most in vitro studies use continuous treatment so that activity never recovers. Replacing continuous treatment with 1 h-pulse treatment increases differences in sensitivity in a panel of 7 multiple myeloma cell lines from 5.3-fold to 18-fold, and reveals that the more sensitive cell lines undergo apoptosis at faster rates. Clinically achievable inhibition of active sites was sufficient to induce cytotoxicity only in one cell line. At concentrations of bortezomib that produced similar inhibition of peptidase activities a different extent of inhibition of protein degradation was observed, providing an explanation for the differential sensitivity. The amount of protein degraded per number of active proteasomes correlated with sensitivity to bortezomib. Thus, (i) in vitro studies of proteasome inhibitors should be conducted at pharmacologically achievable concentrations and duration of treatment; (ii) a similar level of inhibition of active sites results in a different extent of inhibition of protein breakdown in different cell lines, and hence a difference in sensitivity.
ACCESSION #
87624314

 

Related Articles

  • Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.  // Molecular Cancer;2011, Vol. 10 Issue 1, p104 

    The article discusses a study conducted to know effects of apigenin on Multiple Myeloma (MM) cell lines and on primary MM cells. It has been stated that apigenin exhibits cytotoxicity against both MM cell lines and primary MM cells, but induces apoptosis in human multiple myeloma cells through...

  • Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Chen, Feng; Pisklakova, Alexandra; Li, Ming; Baz, Rachid; Sullivan, Daniel; Nefedova, Yulia // Cellular Oncology (2211-3428);Dec2011, Vol. 34 Issue 6, p545 

    Background: Targeting of Notch signaling with γ-secretase inhibitors (GSIs) has been considered a promising strategy for the treatment of hematological malignancies including multiple myeloma (MM). Here we investigated whether the cytotoxic effect of bortezomib, an agent commonly used in MM,...

  • Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells. Roy, Sudipa; Kirma, Nameer; Santhamma, Bindu; Tekmal, Rajeshwar; Agyin, Joseph // Cancer Chemotherapy & Pharmacology;Jun2014, Vol. 73 Issue 6, p1263 

    Proteasome inhibition is associated with substantial antitumor effects in preclinical models of multiple myeloma (MM) as well as in patients. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib (Velcade, also called PS-341) in MM patients have...

  • Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Suzuki, R; Hideshima, T; Mimura, N; Minami, J; Ohguchi, H; Kikuchi, S; Yoshida, Y; Gorgun, G; Cirstea, D; Cottini, F; Jakubikova, J; Tai, Y-T; Chauhan, D; Richardson, P G; Munshi, N C; Utsugi, T; Anderson, K C // Leukemia (08876924);Feb2015, Vol. 29 Issue 2, p510 

    The article presents the study on the anti-tumor activities of selective heat shock protein 90 (HSPO) inhibitor, TAS-116, combined with bortezomib in treating multiple myeloma (MM). It discusses how the study was conducted which involved in vitro and in vivo preclinical anti-MM activity of...

  • Correction.  // Marine Drugs;Oct2014, Vol. 12 Issue 10, p5123 

    A correction to the article "Synthesis, Cytotoxicity and Apoptosis Induction in Human Tumor Cells by Galaxamide and Its Analogues" is presented that was published in the September 30, 2014 issue of the journal.

  • HYPERVISCOSITY SYNDROME: NURSES' ROLE IN THE MANAGEMENT AND TREATMENT OF THIS ONCOLOGIC EMERGENCY. Mullen, Ellen; Mendez, Noel; Mullen, Daniel // Oncology Nursing Forum;Mar2007, Vol. 34 Issue 2, p537 

    Hyperviscosity syndrome (HVS) is a complication that is associated with plasma cell dyscrasias. Plasma cell dyscrasias is a group of related disorders such as Multiple Myeloma (MM), Waldenstrom's macroglobulinemia. It is seen approximately 2-10% in MM and 10-30% in WM. HVS is the term used to...

  • From GC-rich DNA binding to the repression of survivin gene for quercetin nickel (II) complex: implications for cancer therapy. Tan, Jun; Zhu, Liancai; Wang, Bochu // BioMetals;Dec2010, Vol. 23 Issue 6, p1075 

    The DNA binding and cleavage properties of quercetin nickel (II) complex have been studied, but little attention has been devoted to the relationship between antitumor activity of this complex and DNA-binding properties. In the present study, we report that quercetin nickel (II) complex showed...

  • Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells Sarkar, Subhashis; Germeraad, Wilfred T. V.; Rouschop, Kasper M. A.; Steeghs, Elisabeth M. P.; Gelder, Michel van; Bos, Gerard M. J.; Wieten, Lotte // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background: Multiple Myeloma (MM) is an incurable plasma cell malignancy residing within the bone marrow (BM). We aim to develop allogeneic Natural Killer (NK) cell immunotherapy for MM. As the BM contains hypoxic regions and the tumor environment can be immunosuppressive, we hypothesized that...

  • Cytotoxic Effect of Zoledronic Acid-Loaded Bone Cement on Giant Cell Tumor, Multiple Myeloma, and Renal Cell Carcinoma Cell Lines. Zwolak, Pawel; Manivel, J. Carlos; Jasinski, Piotr; Kirstein, Mark N.; Dudek, Arkadiusz Z.; Fisher, James; Cheng, Edward Y. // Journal of Bone & Joint Surgery, American Volume;Jan2010, Vol. 92-A Issue 1, p162 

    Background: Local recurrence with subsequent osteolysis is a problem after intralesional curettage of giant cell tumor of bone, rnyeloma, and metastatic carcinoma. The bisphosphonate zoledronic acid (zoledronate) has been shown to reduce osteoclast activity, and its local administration is a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics